Vogenx

CompanyUnited StatesFounded 2021

Vogenx develops one asset, in phase 2 (Mizagliflozin in postbariatric hypoglycemia). Mostly small molecule; based in the United States, founded in 2021.

1
Asset
Furthest stage
Phase 2
Raised
$81M
2
Trials
4
Signals

Pipeline

1
  • Mizagliflozin

    Inhibits intestinal SGLT1 to reduce glucose absorption and blunt postprandial glucose excursions.

    Phase 2, Small molecule, postbariatric hypoglycemia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials2
  • Funding rounds and grants1
  • Deals1
  • People6
  • Signals7

Intelligence